Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

19 August 2022: Original Paper

Risk Factors for Erythrocytosis in Renal Transplantation: Is Ganciclovir Therapy One of Them?

Fatma Özge Kayhan Koçak 1ABCDEF* , Musa Bali 2ADEF

DOI: 10.12659/AOT.936814

Ann Transplant 2022; 27:e936814

Table 1 Characteristics of patients.

PTE group (n=43)Non-PTE group (n=142)P value
Male, No. (%)39 (90.7%)84 (59.2%)
Living donor, No (%)37 (86%)96 (67.6%)
Cause of ESRD
 Hypertension No. (%)11 (25.6%)14 (9.9%)
MAP, mmHg90±12.194.8±13
Immunosuppressive drug, No. (%)
 mTOR7 (16.3%)15 (10.6%)0.31
 CNI36 (83.7%)128 (90.1%)0.25
 MMF/azathioprine126 (88.7%)39 (90.7%)0.48
ACEi/ARB, No. (%)10 (23.3%)39 (27.5%)0.58
CMV prophylaxis, No. (%)24 (55.8%)54 (38%)
GFR (ml/min)72±21.662.5±27.7
ALT23.3±10.218.4±9.4
Calcium9.8±0.719.5±0.58
ESRD – End-Stage Renal Disease; MAP – mean arterial pressure; ACEi/ARB – angiotensin-converting enzyme inhibitor/angiotensinogen receptor blocker; CNI – calcineurin inhibitor; MMF – mycophenolate mofetil; mTORi – mammalian target of rapamycin inhibitor; GFR – glomerular filtration rate; ALT – alanine aminotransferase; CMV – cytomegalovirus.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358